Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Emerging roles of ILC2s in antitumor immunity

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells: 10 years on.Cells. 2018;174:1054–66.

    Article  CAS  Google Scholar 

  2. Wagner M, Ealey KN, Tetsu H, Kiniwa T, Motomura Y, Moro K, et al. Tumor-derived lactic acid contributes to the paucity of intratumoral ILC2s. Cell Rep. 2020;30:2743–57.e2745.

    Article  PubMed  CAS  Google Scholar 

  3. Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22:851–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Long A, Dominguez D, Qin L, Chen S, Fan J, Zhang M, et al. Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J Immunol. 2018;201:3456–64.

    Article  PubMed  CAS  Google Scholar 

  5. Schuijs MJ, Png S, Richard AC, Tsyben A, Hamm G, Stockis J, et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol. 2020;21:998–1009.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Qi J, Crinier A, Escaliere B, Ye Y, Wang Z, Zhang T, et al. Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression. Cell Rep Med. 2021;2:100353.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Wang S, Qu Y, Xia P, Chen Y, Zhu X, Zhang J, et al. Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer. Cell Res. 2020;30:610–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Jou E, Rodriguez-Rodriguez N, Ferreira AF, Jolin HE, Clark PA, Sawmynaden K, et al. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis. Sci Immunol. 2022;7:eabn0175.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Huang Q, Jacquelot N, Preaudet A, Hediyeh-Zadeh S, Souza-Fonseca-Guimaraes F, McKenzie ANJ, et al. Type 2 innate lymphoid cells protect against colorectal cancer progression and predict improved patient survival. Cancers. 2021;13:559.

  10. Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T, et al. PPAR drives IL-33-dependent ILC2 pro-tumoral functions. Nat Commun. 2021;12:2538.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579:130–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Alam A, Levanduski E, Denz P, Villavicencio HS, Bhatta M, Alhorebi L, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer cell. 2022;40:153–167.e111.

    Article  PubMed  CAS  Google Scholar 

  13. Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salome B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8:593.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wu L, Lin Q, Ma Z, Chowdhury FA, Mazumder MHH, Du W. Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. Leukemia. 2020;34:3028–41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Shen C, Liu C, Zhang Z, Ping Y, Shao J, Tian Y, et al. PD-1 Affects the immunosuppressive function of group 2 innate lymphoid cells in human non-small cell lung cancer. Front Immunol. 2021;12:680055.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references


This work was supported by grants 2020YFA0509103 and 2019YFA0802502 to JQ from the Ministry of Science and Technology of China, grants 32022027 and 31970860 to JQ from the National Natural Science Foundation of China and grants 22ZR1481800 and 20ZR1466900 to JQ from Shanghai Science and Technology Committee (STCSM).

Author information

Authors and Affiliations



ZL, HS, ZG and JQ drafted and edited the manuscript. JQ and ZG performed final proofreading of the manuscript.

Corresponding authors

Correspondence to Zhitao Gu or Ju Qiu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, Z., Sun, H., Gu, Z. et al. Emerging roles of ILC2s in antitumor immunity. Cell Mol Immunol 19, 1311–1313 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links